EUVIMEDEUVIMED entdecken
Übersichtsarbeit

KRAS inhibitors in drug resistance and potential for combination therapy

Lala S Rathod, Nikhil S Sakle, Santosh N Mokale iD

Tumori Journal · 2025

DOI: 10.1177/03008916241289206 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Tumori Journal, 2025. Verfasst von Lala S Rathod und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Antineoplastic Combined Chemotherapy Protocols, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 124 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kirsten Rat Sarcoma (KRAS) is a potent target for cancer therapy because it acts as a signaling hub, engaging in various signaling pathways and regulating a number of cellular functions like cell differentiation, proliferation, and survival. Recently, an emergency approval from the US-FDA has been issued for KRAS G12C inhibitors (sotorasib and adagrasib) for metastatic lung cancer treatment. However, clinical studies on covalent KRAS G12C inhibitors have rapidly confronted resistance in patients. Many methods are being assessed to overcome this resistance, along with various combinatorial clinical studies that are in process. Moreover, because KRAS G12D and KRAS G12V are more common than KRAS G12C , focus must be placed on the therapeutic strategies for this type of patient, along with sustained efforts in research on these targets. In the present review, we try to focus on various strategies to overcome rapid resistance through the use of combinational treatments to improve the activity of KRAS G12C inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)Drug Resistance, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsNeoplasmsAntineoplastic AgentsHumansMolecular Targeted TherapySignal TransductionMutationLung NeoplasmsPiperazinesPyridinesPyrimidines

Stichwörter der Autor:innen

KRASG12C inhibitorsKRASG12D reversible inhibitorsMTRX1133adagrasibcombination therapyresistancesotorasib

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humansotorasibAntineoplastic AgentsPiperazinesPyridinesPyrimidines

Autor:innen und Institutionen

ORCID-Profile: Santosh N Mokale

Zitieren

APA

Rathod, L. S., Sakle, N. S., & Mokale, S. N. (2025). KRAS inhibitors in drug resistance and potential for combination therapy. Tumori Journal. https://doi.org/10.1177/03008916241289206

Vancouver

Rathod LS, Sakle NS, Mokale SN. KRAS inhibitors in drug resistance and potential for combination therapy. Tumori Journal. 2025. doi:10.1177/03008916241289206

BibTeX
@article{Rathod2025,
  author = {Rathod, Lala S and Sakle, Nikhil S and Mokale, Santosh N},
  title = {KRAS inhibitors in drug resistance and potential for combination therapy},
  journal = {Tumori Journal},
  year = {2025},
  doi = {10.1177/03008916241289206}
}
Kostenlos starten →